<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856358</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3121-CL-103</org_study_id>
    <secondary_id>2020-004174-21</secondary_id>
    <nct_id>NCT04856358</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG3121-modified Release Formulation in Adult, Healthy, Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to examine the safety and tolerability of GLPG3121-modified release&#xD;
      formulation when given to healthy male subjects once as a single dose or multiple times over&#xD;
      a period of 14 days in fasting condition or after a standard breakfast.&#xD;
&#xD;
      The study will evaluate how the body absorbs and breaks down GLPG3121, and how GLPG3121 and&#xD;
      the major breakdown product of GLPG3121 are eliminated from the body. In addition, the study&#xD;
      will investigate the effect of food (high-fat) after a single oral dose of GLPG3121 as&#xD;
      modified release tablet.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 Single Ascending Dose (SAD) and Part 2 Multiple Ascending Dose (MAD) are randomized, double-blind, placebo-controlled; Part 3 Food-effect (FE) is randomized, open-label, crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of treatment emergent adverse events (TEAEs), treatment-emergent serious adverse events, and TEAEs leading to treatment discontinuations</measure>
    <time_frame>From screening through study completion, an average of 8 months</time_frame>
    <description>To evaluate the safety and tolerability of single and multiple ascending oral doses of GLPG3121-modified-release formulation (GLPG3121-MR), in adult, healthy, male subjects compared with placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG3121 in SAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 6</time_frame>
    <description>To evaluate the pharmacokinetics (PK) of single ascending oral doses of GLPG3121 in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GLPG3121's main metabolite in SAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 6</time_frame>
    <description>To evaluate the PK of single ascending oral doses of GLPG3121's metabolite in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GLPG3121 in MAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 19</time_frame>
    <description>To evaluate the PK of multiple ascending oral doses of GLPG3121 in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GLPG3121's main metabolite in MAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 19</time_frame>
    <description>To evaluate the PK of multiple ascending oral doses of GLPG3121's main metabolite in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of GLPG3121 in SAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 6</time_frame>
    <description>To evaluate the PK of single ascending oral doses of GLPG3121 in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of GLPG3121's main metabolite in SAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 6</time_frame>
    <description>To evaluate the PK of single ascending oral doses of GLPG3121's main metabolite in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of GLPG3121 in MAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 19</time_frame>
    <description>To evaluate the PK of multiple ascending oral doses of GLPG3121 metabolite in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of GLPG3121's main metabolite in MAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 19</time_frame>
    <description>To evaluate the PK of multiple ascending oral doses of GLPG3121's main metabolite in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of GLPG3121 in SAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 6</time_frame>
    <description>To evaluate the PK of single ascending oral doses of GLPG3121 in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of GLPG3121's main metabolite in SAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 6</time_frame>
    <description>To evaluate the PK of single ascending oral doses of GLPG3121's main metabolite in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of GLPG3121 in MAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 19</time_frame>
    <description>To evaluate the PK of multiple ascending oral doses of GLPG3121 in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of GLPG3121's main metabolite in MAD</measure>
    <time_frame>Between Day 1 pre-dose and Day 19</time_frame>
    <description>To evaluate the PK of multiple ascending oral doses of GLPG3121's main metabolite in adult, healthy, male subjects</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLPG3121 SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of GLPG3121 at up to 3 dose levels in ascending order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3121 MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of GLPG3121 at up to 3 dose levels in ascending order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3121 FE fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3121 in fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3121 FE fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3121 in fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3121</intervention_name>
    <description>GLPG3121 modified-release tablet</description>
    <arm_group_label>GLPG3121 FE fasted</arm_group_label>
    <arm_group_label>GLPG3121 FE fed</arm_group_label>
    <arm_group_label>GLPG3121 MAD</arm_group_label>
    <arm_group_label>GLPG3121 SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_label>Placebo SAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male between 18 and 55 years of age (extremes included), on the date of signing the&#xD;
             informed consent form (ICF).&#xD;
&#xD;
          -  A body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Judged to be in good health by the investigator based upon the results of a medical&#xD;
             history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and&#xD;
             fasting clinical laboratory safety tests, available at screening and prior to&#xD;
             randomization. Hemoglobin, neutrophil, lymphocyte, and platelet counts must be above&#xD;
             the lower limit of normal range. Total bilirubin, aspartate aminotransferase (AST),&#xD;
             alanine aminotransferase (ALT), and serum creatinine must be no greater than the upper&#xD;
             limit of normal (ULN). Other clinical laboratory safety test results must be within&#xD;
             the reference ranges or test results that are outside the reference ranges need to be&#xD;
             considered not clinically significant in the opinion of the investigator.&#xD;
&#xD;
          -  Subject must be able and willing to comply with restrictions on prior and concomitant&#xD;
             medication.&#xD;
&#xD;
          -  Negative screen for drugs (amphetamines, barbiturates, benzodiazepines, cannabis,&#xD;
             cocaine, opiates, methadone, tricyclic antidepressants) and alcohol.&#xD;
&#xD;
        This list only contains the key inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to investigational product (IP) ingredients or history of a&#xD;
             significant allergic reaction to IP ingredients as determined by the investigator.&#xD;
&#xD;
          -  Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus&#xD;
             (HCV) or history of hepatitis from any cause with the exception of hepatitis A that&#xD;
             was resolved at least 3 months prior to first dosing of the IP.&#xD;
&#xD;
          -  History of or a current immunosuppressive condition (e.g. human immunodeficiency virus&#xD;
             [HIV] infection).&#xD;
&#xD;
          -  Having any illness, judged by the investigator as clinically significant, in the 3&#xD;
             months prior to first dosing of the IP.&#xD;
&#xD;
          -  Presence or sequelae of gastrointestinal, liver, kidney (estimated glomerular&#xD;
             filtration rate [eGFR] &lt;=90 mL/min/1.73 m2, using the Chronic Kidney Disease&#xD;
             Epidemiology Collaboration [CKD-EPI] formula) or other conditions known to interfere&#xD;
             with the absorption, distribution, metabolism, or excretion of drugs.&#xD;
&#xD;
        This list only contains the key exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Petkova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galapagos Medical Information</last_name>
    <phone>+32 15 34 29 00</phone>
    <email>medicalinfo@glpg.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité Research Organisation GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

